[Alpha Biz= Reporter Kim Jisun] PharmaResearch has secured a 200 billion KRW investment from CVC Capital, a European-based global private equity firm.
On the 5th, PharmaResearch announced its decision to issue new shares through a third-party allotment worth 200 billion KRW to Polish Company Limited. This capital raise will be conducted by issuing redeemable convertible preferred shares (RCPS) to secure the funds.
Polish Company Limited is a special purpose company (SPC) established by CVC Capital, a global private equity firm headquartered in Luxembourg, managing approximately 193 billion euros (around 280 trillion KRW) in assets.
PharmaResearch plans to significantly boost its investment in research and development (R&D). The company aims to allocate additional resources for the development of new products and the enhancement of existing ones, striving to improve global competitiveness and continue securing innovative technologies.
PharmaResearch anticipates that CVC Capital's extensive experience in the global healthcare industry will help the company offer more differentiated value to its global customers.
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
